Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis
Table 1
Main epidemiologic, clinical, and ultrasonography features of a series of 73 ankylosing spondylitis patients without cardiovascular events, diabetes mellitus, or chronic kidney disease between 35 and 50 years.
Variable
AS ()
Men/women,
44/29
Age at the time of study (years), mean ± SD
Age at the time of diagnosis (years), mean ± SD
Delay to disease diagnosis (years), mean ± SD
Disease duration (years), median (IQR)
Since first symptoms
12.00 (7.00–19.50)
Since diagnosis of AS
5.00 (1.00–9.00)
BASDAI, mean ± SD
ASDAS, mean ± SD
BASFI, mean ± SD
BASMI, mean ± SD
MASES, median (IQR)
1.00 (0.00–4.00)
Extra-articular manifestations, (%)
21 (28.77)
Psoriasis, (%)
8 (10.96)
Inflammatory bowel disease, (%)
3 (4.11)
Uveitis, (%)
14 (19.18)
History of synovitis or enthesitis, (%)
36 (49.32)
Syndesmophytes, (%)
22 (30.14)
Therapy, (%)
Anti-TNF
32 (43.84)
DMARDs
35 (47.95)
NSAIDs
66 (90.41)
Corticosteroids
15 (20.55)
HLA-B27 positive, (%)
55 (75.34)
CRP (mg/l), median (IQR)
At time of study
2.00 (0.50–6.00)
At time of disease diagnosis
4.00 (2.00–10.50)
CRP > 3 mg/L at time of disease diagnosis, (%)
38 (52.05)
ESR (mm/1st hour), median (IQR)
At time of study
6.00 (3.00–14.50)
At time of disease diagnosis
10.00 (4.50–17.50)
History of classic cardiovascular risk factors, (%)
